LITS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Lite Strategy Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerLITS

Market Cap32.1M

Cash RunwayRunway < 6 months

Next Catalyst2028-09

Public Research Snapshot

Lite Strategy Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Busulfan in Multiple Myeloma (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Busulfan	Multiple Myeloma	n/a	Phase 2	Public pipeline row
Brief, Integrated Intervention for Women Veterans with Unhealthy Alcohol Use in Primary Care	Alcohol Misuse	n/a	Na	Public pipeline row
WW Intervention	Diabetes Mellitus \| Type 2 Diabetes \| Obesity	n/a	Na	Public pipeline row
Therapeutic Education System (TES)	Computer-assisted, Evidence-based Psychosocial Intervention \| for Substance Abuse Treatment	n/a	Na	Public pipeline row
myWW App, Virtual Workshops, and Private Facebook Group	Weight Loss	n/a	Na	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2028-09	Brief, Integrated Intervention for Women Veterans with Unhealthy Alcohol Use in Primary Care	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01277939	Na	COMPLETED	376	2011-08
NCT04302389	Na	COMPLETED	153	2021-11-01
NCT01702831	Phase 2	COMPLETED	78	2022-07-31
NCT05935514	Na	COMPLETED	152	2025-10-23
NCT07414589	Na	NOT_YET_RECRUITING	70	2028-09

Scientific Context

asset_name | Brief, Integrated Intervention for Women Veterans with Unhealthy Alcohol Use in Primary Care
catalyst_date_estimated | 2028-09
catalyst_type | Clinical Trial Completion
clinical_stage | Na
clinical_stage | Na

Want the full LITS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.